26 related articles for article (PubMed ID: 10336236)
1. Detection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybrene.
Jacobsen EM; Trettenes EJ; Wisløff F; Abildgaard U
Thromb J; 2006 Jan; 4():3. PubMed ID: 16436199
[TBL] [Abstract][Full Text] [Related]
2. Antiphospholipid antibodies and the endothelium.
Hunt BJ; Khamashta MA
Curr Rheumatol Rep; 2000 Jun; 2(3):252-5. PubMed ID: 11123067
[TBL] [Abstract][Full Text] [Related]
3. Tissue factor pathway inhibitor activity in patients with IDDM.
Leurs PB; van Oerle R; Hamulyak K; Wolffenbuttel BH
Diabetes; 1995 Jan; 44(1):80-4. PubMed ID: 7813818
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
[TBL] [Abstract][Full Text] [Related]
5. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus.
Adams MJ; Palatinus AA; Harvey AM; Khalafallah AA
Lupus; 2011 Dec; 20(14):1474-83. PubMed ID: 21993387
[TBL] [Abstract][Full Text] [Related]
6. Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin.
Hansen JB; Svensson B; Sandset PM; Thijssen F
Thromb Res; 2000 Dec; 100(5):389-96. PubMed ID: 11150580
[TBL] [Abstract][Full Text] [Related]
7. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.
Ariëns RA; Alberio G; Moia M; Mannucci PM
Thromb Haemost; 1999 Feb; 81(2):203-7. PubMed ID: 10063992
[TBL] [Abstract][Full Text] [Related]
8. Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor?
Jacobsen EM; Sandset PM; Wisløff F
Thromb Res; 1999 May; 94(4):213-20. PubMed ID: 10336236
[TBL] [Abstract][Full Text] [Related]
9. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations.
Ostergaard P; Nordfang O; Petersen LC; Valentin S; Kristensen H
Haemostasis; 1993 Mar; 23 Suppl 1():107-11. PubMed ID: 8388348
[TBL] [Abstract][Full Text] [Related]
10. Heparin/low molecular weight heparin and tissue factor pathway inhibitor.
Abildgaard U
Haemostasis; 1993 Mar; 23 Suppl 1():103-6. PubMed ID: 8388347
[TBL] [Abstract][Full Text] [Related]
11. The present status of tissue factor pathway inhibitor.
Lindahl AK; Sandset PM; Abildgaard U
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):439-49. PubMed ID: 1420819
[TBL] [Abstract][Full Text] [Related]
12. Physiological function of tissue factor pathway inhibitor and interaction with heparins.
Sandset PM; Bendz B; Hansen JB
Haemostasis; 2000; 30 Suppl 2():48-56. PubMed ID: 11251341
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
